|
[1]
|
Fakhouri, F., Frémeaux-Bacchi, V., Noël, L., Cook, H.T. and Pickering, M.C. (2010) C3 Glomerulopathy: A New Classification. Nature Reviews Nephrology, 6, 494-499. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Pickering, M.C., D’Agati, V.D., Nester, C.M., Smith, R.J., Haas, M., Appel, G.B., et al. (2013) C3 Glomerulopathy: Consensus Report. Kidney International, 84, 1079-1089. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Ahmad, S.B. and Bomback, A.S. (2020) C3 Glomerulopathy: Pathogenesis and Treatment. Advances in Chronic Kidney Disease, 27, 104-110. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Drake, K.A., Ellington, N., Gattineni, J., Torrealba, J.R. and Hendricks, A.R. (2019) Clinicopathological Features of C3 Glomerulopathy in Children: A Single-Center Experience. Pediatric Nephrology, 35, 153-162. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Cook, H.T. (2018) Evolving Complexity of Complement-Related Diseases: C3 Glomerulopathy and Atypical Haemolytic Uremic Syndrome. Current Opinion in Nephrology and Hypertension, 27, 165-170. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Caravaca-Fontán, F., Díaz-Encarnación, M.M., Lucientes, L., Cavero, T., Cabello, V., Ariceta, G., et al. (2020) Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease. Clinical Journal of the American Society of Nephrology, 15, 1287-1298. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Caravaca-Fontán, F., Lucientes, L., Cavero, T. and Praga, M. (2020) Update on C3 Glomerulopathy: A Complement-Mediated Disease. Nephron, 144, 272-280. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Bomback, A.S., Santoriello, D., Avasare, R.S., Regunathan-Shenk, R., Canetta, P.A., Ahn, W., et al. (2018) C3 Glomerulonephritis and Dense Deposit Disease Share a Similar Disease Course in a Large United States Cohort of Patients with C3 Glomerulopathy. Kidney International, 93, 977-985. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Servais, A., Noël, L., Roumenina, L.T., Le Quintrec, M., Ngo, S., Dragon-Durey, M., et al. (2012) Acquired and Genetic Complement Abnormalities Play a Critical Role in Dense Deposit Disease and Other C3 Glomerulopathies. Kidney International, 82, 454-464. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Iatropoulos, P., Daina, E., Curreri, M., Piras, R., Valoti, E., Mele, C., et al. (2018) Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative Gn. Journal of the American Society of Nephrology, 29, 283-294. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Zahir, Z., Wani, A.S., Gupta, A. and Agrawal, V. (2021) Pediatric C3 Glomerulopathy: A 12-Year Single-Center Experience. Pediatric Nephrology, 36, 601-610. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Wong, E.K.S., Marchbank, K.J., Lomax-Browne, H., Pappworth, I.Y., Denton, H., Cooke, K., et al. (2021) C3 Glomerulopathy and Related Disorders in Children. Clinical Journal of the American Society of Nephrology, 16, 1639-1651. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Medjeral-Thomas, N.R., O’Shaughnessy, M.M., O’Regan, J.A., Traynor, C., Flanagan, M., Wong, L., et al. (2014) C3 Glomerulopathy. Clinical Journal of the American Society of Nephrology, 9, 46-53. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Caravaca-Fontán, F., Trujillo, H., Alonso, M., Díaz-Encarnación, M., Cabello, V., Ariceta, G., et al. (2021) Validation of a Histologic Scoring Index for C3 Glomerulopathy. American Journal of Kidney Diseases, 77, 684-695.e1. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Heiderscheit, A.K., Hauer, J.J. and Smith, R.J.H. (2022) C3 Glomerulopathy: Understanding an Ultra‐Rare Complement‐mediated Renal Disease. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 190, 344-357. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Ueda, C., Horinouchi, T., Inoki, Y., Ichikawa, Y., Tanaka, Y., Kitakado, H., et al. (2024) Clinical Characteristics and Outcomes of Immune-Complex Membranoproliferative Glomerulonephritis and C3 Glomerulopathy in Japanese Children. Pediatric Nephrology, 39, 2679-2689. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Reddy, S., Ghante, A., Vankalakunti, M. and Vasudevan, A. (2025) C3 Glomerulopathy in Children: Experience at a Resource-Limited Center. Clinical and Experimental Pediatrics, 68, 311-318. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Goodship, T.H.J., Cook, H.T., Fakhouri, F., Fervenza, F.C., Frémeaux-Bacchi, V., Kavanagh, D., et al. (2017) Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy: Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney International, 91, 539-551. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
McCarney, J., Curran, K., Peto, T., Silvestri, G. and Cushley, L.N. (2025) The Retinal Complications of C3 Dense Deposit Disease: A Scoping Review. Vision, 9, Article 64. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Ponticelli, C., Calatroni, M. and Moroni, G. (2023) C3 Glomerulopathies: Dense Deposit Disease and C3 Glomerulonephritis. Frontiers in Medicine, 10, Article 1289812. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Meri, S. and Haapasalo, K. (2020) Function and Dysfunction of Complement Factor H during Formation of Lipid-Rich Deposits. Frontiers in Immunology, 11, Article 611830. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Smith, R.J.H., Appel, G.B., Blom, A.M., Cook, H.T., D’Agati, V.D., Fakhouri, F., et al. (2019) C3 Glomerulopathy—Understanding a Rare Complement-Driven Renal Disease. Nature Reviews Nephrology, 15, 129-143. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
盛爱芹. C3肾小球病的研究进展[J]. 国际儿科学杂志, 2022, 49(7): 433-437.
|
|
[24]
|
Madden, B., Singh, R.D., Haas, M., Palma, L.M.P., Sharma, A., Vargas, M.J., et al. (2024) Apolipoprotein E Is Enriched in Dense Deposits and Is a Marker for Dense Deposit Disease in C3 Glomerulopathy. Kidney International, 105, 1077-1087. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Fakhouri, F., Le Quintrec, M. and Frémeaux-Bacchi, V. (2020) Practical Management of C3 Glomerulopathy and Ig-Mediated MPGN: Facts and Uncertainties. Kidney International, 98, 1135-1148. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Meuleman, M., Petitprez, F., Pickering, M.C., Le Quintrec, M., Artero, M.R., Duval, A., et al. (2024) Complement Terminal Pathway Activation and Intrarenal Immune Response in C3 Glomerulopathy. Journal of the American Society of Nephrology, 35, 1034-1044. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Meuleman, M.S., Vieira-Martins, P., El Sissy, C., Audard, V., Baudouin, V., Bertrand, D., et al. (2023) Rare Variants in Complement Gene in C3 Glomerulopathy and Immunoglobulin-Mediated Membranoproliferative GN. Clinical Journal of the American Society of Nephrology, 18, 1435-1445. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Martín Merinero, H., Zhang, Y., Arjona, E., del Angel, G., Goodfellow, R., Gomez-Rubio, E., et al. (2021) Functional Characterization of 105 Factor H Variants Associated with Ahus: Lessons for Variant Classification. Blood, 138, 2185-2201. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Chauvet, S., Roumenina, L.T., Bruneau, S., Marinozzi, M.C., Rybkine, T., Schramm, E.C., et al. (2016) A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H. Journal of the American Society of Nephrology, 27, 1665-1677. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Zipfel, P.F., Wiech, T., Stea, E.D. and Skerka, C. (2020) CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. Journal of the American Society of Nephrology, 31, 241-256. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Antonucci, L., Thurman, J.M. and Vivarelli, M. (2024) Complement Inhibitors in Pediatric Kidney Diseases: New Therapeutic Opportunities. Pediatric Nephrology, 39, 1387-1404. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Donadelli, R., Pulieri, P., Piras, R., Iatropoulos, P., Valoti, E., Benigni, A., et al. (2018) Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN. Frontiers in Immunology, 9, Article 2329. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Andrighetto, S., Leventhal, J., Zaza, G. and Cravedi, P. (2019) Complement and Complement Targeting Therapies in Glomerular Diseases. International Journal of Molecular Sciences, 20, Article 6336. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Noris, M., Donadelli, R. and Remuzzi, G. (2019) Autoimmune Abnormalities of the Alternative Complement Pathway in Membranoproliferative Glomerulonephritis and C3 Glomerulopathy. Pediatric Nephrology, 34, 1311-1323. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Welsh, S.J., Zhang, Y. and Smith, R.J.H. (2025) Acquired Drivers of C3 Glomerulopathy. Clinical Kidney Journal, 18, sfaf022. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Marinozzi, M., Chauvet, S., Le Quintrec, M., Mignotet, M., Petitprez, F., Legendre, C., et al. (2017) C5 Nephritic Factors Drive the Biological Phenotype of C3 Glomerulopathies. Kidney International, 92, 1232-1241. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Blanc, C., Togarsimalemath, S.K., Chauvet, S., Le Quintrec, M., Moulin, B., Buchler, M., et al. (2015) Anti-Factor H Autoantibodies in C3 Glomerulopathies and in Atypical Hemolytic Uremic Syndrome: One Target, Two Diseases. The Journal of Immunology, 194, 5129-5138. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Marinozzi, M.C., Roumenina, L.T., Chauvet, S., Hertig, A., Bertrand, D., Olagne, J., et al. (2017) Anti-Factor B and Anti-C3B Autoantibodies in C3 Glomerulopathy and IG-Associated Membranoproliferative Gn. Journal of the American Society of Nephrology, 28, 1603-1613. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Michels, M.A.H.M., van de Kar, N.C.A.J., van Kraaij, S.A.W., Sarlea, S.A., Gracchi, V., Engels, F.A.P.T., et al. (2021) Different Aspects of Classical Pathway Overactivation in Patients with C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Frontiers in Immunology, 12, Article 715704. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Hauer, J.J., Zhang, Y., Goodfellow, R., Taylor, A., Meyer, N.C., Roberts, S., et al. (2024) Defining Nephritic Factors as Diverse Drivers of Systemic Complement Dysregulation in C3 Glomerulopathy. Kidney International Reports, 9, 464-477. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Michels, M.A.H.M., Wijnsma, K.L., Kurvers, R.A.J., Westra, D., Schreuder, M.F., van Wijk, J.A.E., et al. (2022) Long-term Follow-Up Including Extensive Complement Analysis of a Pediatric C3 Glomerulopathy Cohort. Pediatric Nephrology, 37, 601-612. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Vivarelli, M., van de Kar, N., Labbadia, R., Diomedi-Camassei, F. and Thurman, J.M. (2022) A Clinical Approach to Children with C3 Glomerulopathy. Pediatric Nephrology, 37, 521-535. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Kavanagh, D., Ariceta, G., Vivarelli, M., Schaefer, F., Caravaca-Fontán, F., Frémeaux-Bacchi, V., et al. (2026) Current and Emerging Therapies for C3 Glomerulopathy and Primary (Idiopathic) Immune Complex Membranoproliferative Glomerulonephritis. Kidney International Reports®, 11, 17-31. [Google Scholar] [CrossRef]
|
|
[44]
|
Nester, C., Decker, D.A., Meier, M., Aslam, S., Bomback, A.S., Caravaca-Fontán, F., et al. (2024) Developing Therapies for C3 Glomerulopathy: Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group. Clinical Journal of the American Society of Nephrology, 19, 1201-1208. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Caravaca-Fontán, F., Fakhouri, F., Licht, C., Pickering, M.C., Schaefer, F. and Wong, E. (2026) Delphi Consensus on Surrogate End Points in C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Kidney International Reports, 11, Article ID: 103671. [Google Scholar] [CrossRef]
|
|
[46]
|
Zhao, W., Ding, Y., Lu, J., Zhang, T., Chen, D., Zhang, H., et al. (2018) Genetic Analysis of the Complement Pathway in C3 Glomerulopathy. Nephrology Dialysis Transplantation, 33, 1919-1927. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Bomback, A.S., Charu, V. and Fakhouri, F. (2025) Challenges in the Diagnosis and Management of Immune Complex-Mediated Membranoproliferative Glomerulonephritis and Complement 3 Glomerulopathy. Kidney International Reports, 10, 17-28. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Wada, Y., Kamata, M., Miyasaka, R., Abe, T., Kawamura, S., Takeuchi, K., et al. (2023) Clinico-Pathogenic Similarities and Differences between Infection-Related Glomerulonephritis and C3 Glomerulopathy. International Journal of Molecular Sciences, 24, Article 8432. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Caravaca-Fontán, F., Lucientes, L., Serra, N., Cavero, T., Rodado, R., Ramos, N., et al. (2022) C3 Glomerulopathy Associated with Monoclonal Gammopathy: Impact of Chronic Histologic Lesions and Beneficial Effects of Clone-Targeted Therapies. Nephrology Dialysis Transplantation, 37, 2128-2137. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
成易兰, 张璐, 王惠明. 单克隆免疫球蛋白相关C3肾小球肾炎研究进展[J]. 临床肾脏病杂志, 2024, 24(3): 229-232.
|
|
[51]
|
Avasare, R.S., Canetta, P.A., Bomback, A.S., Marasa, M., Caliskan, Y., Ozluk, Y., et al. (2018) Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy. Clinical Journal of the American Society of Nephrology, 13, 406-413. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Günay, N., Dursun, İ., Gökçe, İ., Akbalık Kara, M., Tekcan, D., Çiçek, N., et al. (2024) Complement Gene Mutations in Children with C3 Glomerulopathy: Do They Affect the Response to Mycophenolate Mofetil? Pediatric Nephrology, 39, 1435-1446. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Tarragon Estebanez, B. and Bomback, A.S. (2024) C3 Glomerulopathy: Novel Treatment Paradigms. Kidney International Reports, 9, 569-579. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Noris, M. and Remuzzi, G. (2024) C3G and Ig-MPGN—Treatment Standard. Nephrology Dialysis Transplantation, 39, 202-214. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Ali, U.S. and Sathe, K.P. (2025) Favorable Outcome in Children with Dense Deposit Disease with the Use of Long-Term Mycophenolate Mofetil and High-Dose Alternate-Day Steroids. Pediatric Nephrology, 40, 987-993. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Häffner, K., Michelfelder, S. and Pohl, M. (2015) Successful Therapy of C3Nef-Positive C3 Glomerulopathy with Plasma Therapy and Immunosuppression. Pediatric Nephrology, 30, 1951-1959. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Noris, M., Daina, E. and Remuzzi, G. (2023) Membranoproliferative Glomerulonephritis: No Longer the Same Disease and May Need Very Different Treatment. Nephrology Dialysis Transplantation, 38, 283-290. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Apetrii, M., Costache, A.D., Costache Enache, I.I., Voroneanu, L., Covic, A.S., Kanbay, M., et al. (2025) Complement System Inhibitors in Nephrology: An Update—Narrative Review. International Journal of Molecular Sciences, 26, Article 5902. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Welte, T., Arnold, F., Westermann, L., Rottmann, F.A., Hug, M.J., Neumann-Haefelin, E., et al. (2023) Eculizumab as a Treatment for C3 Glomerulopathy: A Single-Center Retrospective Study. BMC Nephrology, 24, Article No. 8. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
Dixit, S., Chang, Y., Ahdoot, R.S., Ham, A. and Hanna, R.M. (2026) C3 Glomerulopathy: Advancements in Diagnostics and Therapeutics. Current Opinion in Nephrology & Hypertension, 35, 52-61. [Google Scholar] [CrossRef]
|
|
[61]
|
Conversano, E. and Vivarelli, M. (2025) Advances in Complement Inhibitory Strategies for the Treatment of Glomerular Disease: A Rapidly Evolving Field. Journal of Clinical Medicine, 14, Article 4204. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Ruggenenti, P., Daina, E., Gennarini, A., Carrara, C., Gamba, S., Noris, M., et al. (2019) C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. American Journal of Kidney Diseases, 74, 224-238. [Google Scholar] [CrossRef] [PubMed]
|
|
[63]
|
Zotta, F., Diomedi-Camassei, F., Gargiulo, A., Cappoli, A., Emma, F. and Vivarelli, M. (2023) Successful Treatment with Avacopan (CCX168) in a Pediatric Patient with C3 Glomerulonephritis. Pediatric Nephrology, 38, 4197-4201. [Google Scholar] [CrossRef] [PubMed]
|
|
[64]
|
Bomback, A.S., Herlitz, L.C., Kedia, P.P., Petersen, J., Yue, H. and Lafayette, R.A. (2025) Safety and Efficacy of Avacopan in Patients with Complement 3 Glomerulopathy. Journal of the American Society of Nephrology, 36, 487-499. [Google Scholar] [CrossRef] [PubMed]
|
|
[65]
|
Wong, E., Nester, C., Cavero, T., Karras, A., Le Quintrec, M., Lightstone, L., et al. (2023) Efficacy and Safety of Iptacopan in Patients with C3 Glomerulopathy. Kidney International Reports, 8, 2754-2764. [Google Scholar] [CrossRef] [PubMed]
|
|
[66]
|
Nester, C.M., Eisenberger, U., Karras, A., le Quintrec, M., Lightstone, L., Praga, M., et al. (2025) Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy. Kidney International Reports, 10, 432-446. [Google Scholar] [CrossRef] [PubMed]
|
|
[67]
|
Kavanagh, D., Bomback, A.S., Vivarelli, M., Nester, C.M., Remuzzi, G., Zhao, M., et al. (2025) Oral Iptacopan Therapy in Patients with C3 Glomerulopathy: A Randomised, Double-Blind, Parallel Group, Multicentre, Placebo-Controlled, Phase 3 Study. The Lancet, 406, 1587-1598. [Google Scholar] [CrossRef]
|
|
[68]
|
Dixon, B.P., Greenbaum, L.A., Huang, L., Rajan, S., Ke, C., Zhang, Y., et al. (2023) Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases. Kidney International Reports, 8, 2284-2293. [Google Scholar] [CrossRef] [PubMed]
|
|
[69]
|
Nester, C.M., Bomback, A.S., Ariceta, G., Delmas, Y., Dixon, B.P., Gale, D.P., et al. (2025) VALIANT: Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Trial of Pegcetacoplan for Patients with Native or Post-Transplant Recurrent C3G or Primary (Idiopathic) IC-MPGN. Immunobiology, 230, Article ID: 153039. [Google Scholar] [CrossRef]
|
|
[70]
|
Fakhouri, F., Bomback, A.S., Ariceta, G., Delmas, Y., Dixon, B.P., Gale, D.P., et al. (2025) Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. New England Journal of Medicine, 393, 2210-2220. [Google Scholar] [CrossRef]
|
|
[71]
|
Podos, S.D., Trachtman, H., Appel, G.B., Bomback, A.S., Dixon, B.P., Wetzels, J.F.M., et al. (2022) Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan. American Journal of Nephrology, 53, 675-686. [Google Scholar] [CrossRef] [PubMed]
|
|
[72]
|
余剑梅, 何伟春. 补体介导免疫性肾病的机制与靶向治疗进展[J]. 实用医学杂志, 2026, 42(5): 899-908.
|
|
[73]
|
Nester, C., Appel, G.B., Bomback, A.S., Bouman, K.P., Cook, H.T., Daina, E., et al. (2022) Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies. American Journal of Nephrology, 53, 687-700. [Google Scholar] [CrossRef] [PubMed]
|
|
[74]
|
Schubart, A., Anderson, K., Mainolfi, N., Sellner, H., Ehara, T., Adams, C.M., et al. (2019) Small-Molecule Factor B Inhibitor for the Treatment of Complement-Mediated Diseases. Proceedings of the National Academy of Sciences of the United States of America, 116, 7926-7931. [Google Scholar] [CrossRef] [PubMed]
|
|
[75]
|
邹军, 蒋更如. 靶向补体治疗在肾病领域的临床应用[J]. 上海医学, 2025, 48(9): 548-551.
|
|
[76]
|
Román Ortiz, E., Sáez Bello, M., Reparaz Suevos, A., Perez Ebri, M., Aguilar Bacallado, F., LLopis Salvia, P., et al. (2026) Pegcetacoplan in Idiopathic and Familial Pediatric C3 Glomerulopathy. Pediatric Nephrology, 41, 1351-1360. [Google Scholar] [CrossRef]
|
|
[77]
|
Mancuso, M.C., Cugno, M., Griffini, S., Grovetti, E., Nittoli, T., Mastrangelo, A., et al. (2025) Efficacy of Complement Inhibition with Pegcetacoplan in Children with C3 Glomerulopathy. Pediatric Nephrology, 40, 1959-1963. [Google Scholar] [CrossRef] [PubMed]
|
|
[78]
|
Guzman, G.L. and Perry, K.W. (2025) Pegcetacoplan for the Treatment of Paediatric C3 Glomerulonephritis: A Case Report. Nephrology, 30, e70001. [Google Scholar] [CrossRef] [PubMed]
|
|
[79]
|
Obata, S., Vaz de Castro, P.A.S., Riella, L.V. and Cravedi, P. (2024) Recurrent C3 Glomerulopathy after Kidney Transplantation. Transplantation Reviews, 38, Article ID: 100839. [Google Scholar] [CrossRef] [PubMed]
|
|
[80]
|
Emma, F. and John, P. (2025) Anticomplement Therapies for C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis Recurrence—A Dawn of New Hope. Kidney International Reports, 10, 7-9. [Google Scholar] [CrossRef] [PubMed]
|
|
[81]
|
Borovitz, Y., Landau, D., Dagan, A., Alfandari, H., Haskin, O., Levi, S., et al. (2024) Childhood Onset C3 Glomerulopathy: Recurrence after Kidney Transplantation—A Case Series. Frontiers in Pediatrics, 12, Article 1460525. [Google Scholar] [CrossRef] [PubMed]
|
|
[82]
|
Patry, C., Webb, N.J.A., Meier, M., Pape, L., Fichtner, A., Höcker, B., et al. (2025) Kidney Transplantation in Children and Adolescents with C3 Glomerulopathy or Immune Complex Membranoproliferative Glomerulonephritis: An International Survey of Current Practice. Pediatric Transplantation, 29, e70048. [Google Scholar] [CrossRef] [PubMed]
|
|
[83]
|
Attieh, R.M., Bharati, J., Sharma, P., Nair, G., Ayehu, G. and Jhaveri, K.D. (2025) Kidney Transplant in Patients with C3 Glomerulopathy. Clinical Kidney Journal, 18, sfaf134. [Google Scholar] [CrossRef] [PubMed]
|
|
[84]
|
Tarragón, B., Peleg, Y., Jagannathan, G., Sekulic, M., Chang, J., Cohen, D.J., et al. (2024) C3 Glomerulopathy Recurs Early after Kidney Transplantation in Serial Biopsies Performed within the First 2 Years after Transplantation. Clinical Journal of the American Society of Nephrology, 19, 1005-1015. [Google Scholar] [CrossRef] [PubMed]
|
|
[85]
|
Caravaca-Fontán, F., Fakhouri, F., Pickering, M.C., Lionikaite, V., Baird, A., Horneff, R., et al. (2025) Clinical Presentation, Treatment Patterns, Burden of Disease, and the Association of Proteinuria with Clinical Outcomes in C3 Glomerulopathy and Primary Immune Complex Membranoproliferative Glomerulonephritis: A Systematic Review. Nephron, 150, 25-40. [Google Scholar] [CrossRef]
|
|
[86]
|
Khandelwal, P., Bhardwaj, S., Singh, G., Sinha, A., Hari, P. and Bagga, A. (2021) Therapy and Outcomes of C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis. Pediatric Nephrology, 36, 591-600. [Google Scholar] [CrossRef] [PubMed]
|
|
[87]
|
Cappoli, A., Kersnik-Levart, T., Silecchia, V., Ariceta, G., Gjerstad, A.C., Ghiggeri, G., et al. (2025) C3 Glomerulopathy in Children: A European Longitudinal Study Evaluating Outcome. Pediatric Nephrology, 40, 979-986. [Google Scholar] [CrossRef] [PubMed]
|
|
[88]
|
Chauvet, S., Hauer, J.J., Petitprez, F., Rabant, M., Martins, P.V., Baudouin, V., et al. (2022) Results from a Nationwide Retrospective Cohort Measure the Impact of C3 and Soluble C5b-9 Levels on Kidney Outcomes in C3 Glomerulopathy: Results from a National-Wide Retrospective Cohort. Kidney International, 102, 904-916. [Google Scholar] [CrossRef] [PubMed]
|
|
[89]
|
Garam, N., Cserhalmi, M., Prohászka, Z., Szilágyi, Á., Veszeli, N., Szabó, E., et al. (2021) FHR-5 Serum Levels and CFHR5 Genetic Variations in Patients with Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy. Frontiers in Immunology, 12, Article 720183. [Google Scholar] [CrossRef] [PubMed]
|
|
[90]
|
Masoud, S., Wong, K., Pitcher, D., Downward, L., Proudfoot, C., Webb, N.J.A., et al. (2025) Quantifying Association of Early Proteinuria and Estimated Glomerular Filtration Rate Changes with Long-Term Kidney Failure in C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis Using the United Kingdom Radar Registry. Kidney International, 108, 455-469. [Google Scholar] [CrossRef] [PubMed]
|